Literature DB >> 24375602

Methicillin-resistant Staphylococcus aureus epidural abscess treated with ceftaroline fosamil salvage therapy.

John Bucheit1, Rebeccah Collins, Prajwol Joshi.   

Abstract

PURPOSE: A case of a patient who received ceftaroline fosamil as salvage therapy for a methicillin-resistant Staphylococcus aureus (MRSA) epidural abscess is reported.
SUMMARY: A 48-year-old white woman arrived at the emergency department (ED) with an altered mental status. She had been to the ED two days prior with complaints of sudden-onset and worsening neck pain. She had a history of compacted disks in her neck secondary to a motor vehicle accident that occurred three years prior but that did not require surgical intervention. Computed tomography and magnetic resonance imaging scans confirmed an epidural abscess with wound cultures growing MRSA. The admitting physician indicated that the patient was severely septic. Acyclovir, ceftriaxone, and vancomycin were initiated for empirical treatment due to suspected meningitis. Paired blood cultures also continued to grow MRSA in four of four bottles collected four days after admission. This indicated that antimicrobial therapy was not successfully eradicating the MRSA found in the blood and the patient's clinical status was deteriorating. Ceftaroline was used as salvage therapy, resulting in rapid clearance of MRSA from the blood and the patient becoming afebrile in 24 hours. Blood culture tests on hospital day 11-one day after ceftaroline initiation-were clear of MRSA. The patient was discharged to a long-term-care facility and ordered ceftaroline fosamil 600 mg i.v. every 12 hours for four weeks.
CONCLUSION: A MRSA epidural abscess in a 48-year-old woman was successfully treated with ceftaroline fosamil 600 mg every 12 hours as salvage therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24375602     DOI: 10.2146/ajhp130246

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  6 in total

1.  In vivo emergence of ceftaroline resistance during therapy for MRSA vertebral osteomyelitis.

Authors:  Edgar H Sanchez; Rodrigo E Mendes; Helio S Sader; Genève M Allison
Journal:  J Antimicrob Chemother       Date:  2016-02-09       Impact factor: 5.790

2.  Ceftaroline Cerebrospinal Fluid Penetration in the Treatment of a Ventriculopleural Shunt Infection: A Case Report.

Authors:  Jeffrey J Cies; Wayne S Moore; Adela Enache; Arun Chopra
Journal:  J Pediatr Pharmacol Ther       Date:  2020

Review 3.  Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review.

Authors:  Reese A Cosimi; Nahal Beik; David W Kubiak; Jennifer A Johnson
Journal:  Open Forum Infect Dis       Date:  2017-05-02       Impact factor: 3.835

4.  MRSA Spinal Epidural Abscess as a Neurosurgical and Infectious Disease Emergency with Unresolved Antimicrobial Solution.

Authors:  James Ebot; W D Freeman; Robert Wharen; Mark Anthony Diaz; Claudia Libertin
Journal:  Case Rep Infect Dis       Date:  2019-01-30

5.  Ceftaroline fosamil: clinical experience after 23-month prescription in a tertiary hospital.

Authors:  A Alonso Álvarez; L Ramos Merino; L M Castelo Corral; A Padín Trigo; D Sousa Regueiro; E Míguez Rey; E Sánchez Vidal
Journal:  Rev Esp Quimioter       Date:  2021-02-15       Impact factor: 1.553

Review 6.  Ceftaroline Fosamil for Treatment of Pediatric Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia.

Authors:  Susanna Esposito; Timothy J Carrothers; Todd Riccobene; Gregory G Stone; Michal Kantecki
Journal:  Paediatr Drugs       Date:  2021-08-31       Impact factor: 3.022

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.